Literature DB >> 29890544

Increased OGA Expression and Activity in Leukocytes from Patients with Diabetes: Correlation with Inflammation Markers.

Patrick Pagesy1,2,3, Caroline Tachet1,2,3, Ali Mostefa-Kara1,2,3, Etienne Larger1,2,3,4, Tarik Issad1,2,3.   

Abstract

O-linked-β-N-Acetylglucosaminylation (O-GlcNAcylation), a reversible post-translational modification involved in diabetic complications, is regulated by only two enzymes, O-linked N-acetylglucosamine transferase (OGT) and β-N-Acetylglucosaminidase (OGA). Increased OGA expression has been described previously in blood cells from patients with diabetes and was interpreted as an adaptative response to hyperglycemia-induced O-GlcNAcylation. OGA expression was thus proposed to have potential utility as a diagnostic marker. The present work was undertaken to determine whether determination of OGA enzymatic activity in blood cells could constitute a more rapidly accessible marker than OGA expression level measurements.Blood samples were obtained from patients with type 2 diabetes from the Department of Diabetology of the Cochin Hospital and healthy volunteers from the French blood Agency. OGA enzymatic activity and OGA mRNA expression levels were evaluated in leucocytes from patients with type 2 diabetes and from healthy donors.OGA activity was higher in leucocytes from patients with diabetes compared to control individuals. Surprisingly, OGA activity was not correlated hyperglycaemia markers (blood glucose, fructosamine, HbA1c) but was positively correlated with the inflammatory marker C-reactive protein. OGA mRNA levels were also increased in leucocytes from patients with diabetes and were correlated with mRNA coding for two pro-inflammatory proteins, TNFα and TxNIP.Therefore, OGA activity in leucocytes might be a more easily accessible biomarker than OGA expression levels. However, changes in OGA activity observed in patients with type 2 diabetes may reflect the inflammatory rather than the glycaemic status of these patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Year:  2018        PMID: 29890544     DOI: 10.1055/a-0596-7337

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  6 in total

1.  Short O-GlcNAcase Is Targeted to the Mitochondria and Regulates Mitochondrial Reactive Oxygen Species Level.

Authors:  Patrick Pagesy; Abdelouhab Bouaboud; Zhihao Feng; Philippe Hulin; Tarik Issad
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

2.  Hyperglycemia-Associated Dysregulation of O-GlcNAcylation and HIF1A Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (SKOV-3).

Authors:  Aneta Rogalska; Ewa Forma; Magdalena Bryś; Agnieszka Śliwińska; Agnieszka Marczak
Journal:  Int J Mol Sci       Date:  2018-09-13       Impact factor: 5.923

3.  O-GlcNAcylation Suppresses the Ion Current IClswell by Preventing the Binding of the Protein ICln to α-Integrin.

Authors:  Roberta Costa; Alessia Remigante; Davide A Civello; Emanuele Bernardinelli; Zoltán Szabó; Rossana Morabito; Angela Marino; Antonio Sarikas; Wolfgang Patsch; Markus Paulmichl; Tamás Janáky; Attila Miseta; Tamás Nagy; Silvia Dossena
Journal:  Front Cell Dev Biol       Date:  2020-11-19

Review 4.  The Emerging Role of TXNIP in Ischemic and Cardiovascular Diseases; A Novel Marker and Therapeutic Target.

Authors:  Alison Domingues; Julia Jolibois; Perrine Marquet de Rougé; Valérie Nivet-Antoine
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

5.  Disruption of O-GlcNAcylation Homeostasis Induced Ovarian Granulosa Cell Injury in Bovine.

Authors:  Teng-Fei Wang; Zhi-Qiang Feng; Ya-Wen Sun; Shan-Jiang Zhao; Hui-Ying Zou; Hai-Sheng Hao; Wei-Hua Du; Xue-Ming Zhao; Hua-Bin Zhu; Yun-Wei Pang
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

Review 6.  Protein O-GlcNAcylation and the regulation of energy homeostasis: lessons from knock-out mouse models.

Authors:  Tarik Issad; Hasanain Al-Mukh; Abdelouhab Bouaboud; Patrick Pagesy
Journal:  J Biomed Sci       Date:  2022-09-04       Impact factor: 12.771

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.